Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma
Johnny Duerinck(Universitair Ziekenhuis Brussel), Anne Rogiers(Centre Hospitalier Universitaire Brugmann), Jean‐François Baurain(Cliniques Universitaires Saint-Luc), Frank Bouttens(AZ Sint-Lucas), Philippe Vroman(Onze Lieve Vrouwziekenhuis Hospital), Pol Specenier(Antwerp University Hospital), Vincent Verschaeve(Grand Charleroi Hospital), Barbara Stragier, Lionel D’hondt(CHU Dinant Godinne UCL Namur), Frank Van Fraeyenhove(ZNA Middelheim Hospital), E. Joosens(Jessa Hospital), Bart Neyns(Universitair Ziekenhuis Brussel), Y. Staelens(Ziekenhuis Oost-Limburg), Chantal André(Inserm), Paul M. Clément(Universitair Ziekenhuis Leuven), Sylvie Luce(Erasmus Hospital), Bertrand Filleul(Cliniques Universitaires Saint-Luc)
Cited by 13
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
|The Lancet|2017|1.2k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869